JR

Jacob Rubens

Scientist Entrepreneur

Cambridge, Massachusetts

Invests in

Stages:

  • Min Investment:

    $500,000.00
  • Max Investment:

    $15,000,000.00
  • Target Investment:

    $7,000,000.00

Work Experience

  • Chief Executive Officer

    2024

  • President

    2021 - 2024

  • Origination Partner

    2023

  • Senior Principal

    2021 - 2023

  • Principal

    2019 - 2021

  • Senior Associate

    2018 - 2019

  • Associate

    2015 - 2018

  • VentureLabs Fellow

    2015 - 2015

  • Co-Founder

    2018

  • Chief Innovation Officer

    2018

  • Chief Scientific Officer

    2018 - 2021

  • Co-Founder

    2019

    Sana Biotechnology, Inc. is focused on creating and delivering engineered cells and gene therapies as medicines. This new class of medicines is based on recent scientific advances that make it possible to treat a broad array of diseases. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that will change how we approach treating disease.

  • Co-Founder and Head of Innovation

    2016 - 2018

    Cobalt Biomedicine is developing a new class of therapeutics based on the ability to deliver into cells essentially any biological payload, ranging from defined molecular polymers to cellular organelles, with unprecedented cell specificity. This approach enables direct and highly targeted intervention inside the cell opening up vast opportunities across diverse therapeutic areas, with the potential to transiently or permanently correct for defects at the root of diseases. Cobalt Biomedicine was founded by Flagship Pioneering.

  • Scientific Strategy and Operations

    2016 - 2016

    Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship Pioneering, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome's natural roles in promoting health.

  • PHD Student

    2010 - 2015

    Synthetic Biology Center with Tim Lu

  • Instructor

    2012 - 2014

    MIT's Office of Engineering Outreach Programs (OEOP) SEED Academy

2014 - 2015

  • Co Founder

    2014 - 2015

    Enterosense worked on a medical device for measuring biomarkers in the gut

  • Project Leader and Team Founder

    2009 - 2010

  • Undergraduate Research Assistant

    2008 - 2010